Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Another Phase III Study Supports Avastin Expansion To Ovarian Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

Adding bevacizumab to chemo in first-line and maintenance therapy gives an undisclosed benefit in progression-free survival.
Advertisement

Related Content

Keeping Track: Keytruda Adds Two New Uses, Furoscix ‘Patch Pump’ Gets A CRL, And Nightstar Nabs An RMAT
FDA Finally Approves Avastin In First-Line Ovarian Cancer
Avastin Stakes Claim In Ovarian Cancer; Other Ovarian Updates At ESMO Are Mixed
Avastin Stakes Claim In Ovarian Cancer; Other Ovarian Updates At ESMO Are Mixed
Clinical Development Setbacks, Pricing Pressures Hit Roche
Clinical Development Setbacks, Pricing Pressures Hit Roche
Clinical Development Setbacks, Pricing Pressures Hit Top, Bottom Lines at Roche
Clinical Development Setbacks, Pricing Pressures Hit Top, Bottom Lines at Roche
Roche's Long View: ASCO Marks Progress In Shifting To Lengthier Treatment Duration For Avastin, Rituxan
Roche's Long View: ASCO Marks Progress In Shifting To Lengthier Treatment Duration For Avastin, Rituxan

Topics

Advertisement
UsernamePublicRestriction

Register

PS070921

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel